NCT07369856 Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure
| NCT ID | NCT07369856 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cardiology Research UBC |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-11-04 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2025-11-04 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Heart failure is a chronic condition that causes congestion and frequent hospitalizations. Diuretic doses are usually adjusted based on clinical judgment without an objective measure of response. This study will test the feasibility of using point-of-care urine sodium measurements to guide up-titration or down-titration of loop diuretics in ambulatory patients with heart failure. Participants will be assigned to one of three groups based on congestion status. Groups 1 and 2 will be randomized 1:1 to natriuresis-guided therapy or standard care. Group 3 will be observational. The 90-day pilot trial will evaluate feasibility, clinical outcomes, and usability of a urine sodium-guided titration strategy.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Diagnosis of heart failure according to the Universal Definition * Use of loop diuretics * Residing in VCH or PHC regions Group-specific inclusion: Group 1: Congestion score ≥5 OR objective congestion; stable furosemide ≥1 week Group 2: NYHA I-II; congestion score \<5; no recent HF hospitalization; stable furosemide ≥1 month Group 3: First 100 eligible patients not meeting criteria for Groups 1 or 2 Exclusion Criteria: * eGFR \<20 mL/min/1.73m² * Renal replacement therapy * High-risk clinical status requiring hospitalization * Inability to consent or perform required urine sampling
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07369856 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07369856 currently recruiting?
Yes, NCT07369856 is actively recruiting participants. Contact the research team at natalie.blochisenberg@vch.ca for enrollment information.
Where is the NCT07369856 trial being conducted?
This trial is being conducted at Vancouver, Canada.
Who is sponsoring the NCT07369856 clinical trial?
NCT07369856 is sponsored by Cardiology Research UBC. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.